Morningside is a venture capital firm based in the greater Boston area, specializing in investments in companies that focus on innovative science and technology. Established in 1986 as a family office for the Chan family, Morningside emphasizes a long-term approach to company-building and maintains a strong commitment to ethical practices. The firm is staffed by a team of experienced investment professionals with expertise in various sectors, including life sciences, digital health, artificial intelligence, materials, and technology. In addition to its investment activities, Morningside is dedicated to philanthropic efforts, supporting education, research, and healthcare initiatives such as the Harvard T.H. Chan School of Public Health, UMass Chan Medical School, and the MIT Morningside Academy for Design.
Stealth BioTherapeutics is a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of therapies targeting diseases linked to mitochondrial dysfunction. Founded in 2006 and based in George Town, Cayman Islands, the company is advancing its lead product candidate, Elamipretide, which aims to address both rare genetic and age-related mitochondrial diseases. Additionally, Stealth BioTherapeutics is developing SBT-20, a small peptide that stabilizes mitochondrial structure and function during oxidative stress, and SBT-272, a compound under evaluation for rare neurodegenerative diseases, including amyotrophic lateral sclerosis. Mitochondria play a crucial role in energy production and overall organ function, making the company's focus on these organelles significant in the biopharmaceutical landscape.
Stealth BioTherapeutics
Post in 2020
Stealth BioTherapeutics is a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of therapies targeting diseases linked to mitochondrial dysfunction. Founded in 2006 and based in George Town, Cayman Islands, the company is advancing its lead product candidate, Elamipretide, which aims to address both rare genetic and age-related mitochondrial diseases. Additionally, Stealth BioTherapeutics is developing SBT-20, a small peptide that stabilizes mitochondrial structure and function during oxidative stress, and SBT-272, a compound under evaluation for rare neurodegenerative diseases, including amyotrophic lateral sclerosis. Mitochondria play a crucial role in energy production and overall organ function, making the company's focus on these organelles significant in the biopharmaceutical landscape.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.